AULSF (Austar Lifesciences) Long-Term Debt: $9.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AULSF Austar Lifesciences Ltd AULSF
49 GF Score
Price $0.02
GF Value $0.08
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Austar Lifesciences Long-Term Debt?

Austar Lifesciences AULSF 49 Long-Term Debt is $9.0 Mil as of Dec. 2025. GuruFocus rates AULSF with a GF Score™ of 49/100 and a GF Value™ of $0.08 (Possible Value Trap). The stock has 6 warning signs investors should review.

Austar Lifesciences's Long-Term Debt for the quarter that ended in Dec. 2025 was $9.0 Mil.

Austar Lifesciences's quarterly Long-Term Debt increased from Dec. 2024 ($3.5 Mil) to Jun. 2025 ($8.6 Mil) and increased from Jun. 2025 ($8.6 Mil) to Dec. 2025 ($9.0 Mil).

Austar Lifesciences's annual Long-Term Debt declined from Dec. 2023 ($15.5 Mil) to Dec. 2024 ($3.5 Mil) but then increased from Dec. 2024 ($3.5 Mil) to Dec. 2025 ($9.0 Mil).

Austar Lifesciences  (OTCPK:AULSF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Austar Lifesciences Long-Term Debt Related Terms

Austar Lifesciences Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Austar Lifesciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Austar Lifesciences Long-Term Debt Chart

Austar Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.52 5.75 15.52 3.45 8.98

Austar Lifesciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.52 10.41 3.45 8.58 8.98
AULSF
49GF Score
Austar Lifesciences Ltd AULSF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $9.0 Mil mean?
Austar Lifesciences (AULSF) has a Long-Term Debt of $9.0 Mil as of Dec. 2025.
Is Austar Lifesciences' Long-Term Debt too high?
Austar Lifesciences' current Long-Term Debt is $9.0 Mil. Overall, Austar Lifesciences has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' Long-Term Debt compare to ABT and SYK?
Austar Lifesciences' Long-Term Debt of $9.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Austar Lifesciences's current Long-Term Debt is $9.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Austar Lifesciences (AULSF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.02 — trading 75% below its estimated fair value. The current Long-Term Debt is $9.0 Mil. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current Long-Term Debt is $9.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Austar Lifesciences (AULSF) Overvalued in 2026?

Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued. The current stock price of $0.02 is trading 75% below its estimated GF Value™ of $0.08. GuruFocus considers Austar Lifesciences to be Possible Value Trap.

Key valuation signals for AULSF:

  • Long-Term Debt: $9.0 Mil
  • GF Value™: $0.08 vs. price of $0.02 (75% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Austar Lifesciences Business Description

Other Exchanges 06118:Hong Kong
Address No.1018 Changning Road, Rooms 2010-2013, 20th Floor, Changning District, Shanghai, CHN
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score

Get the complete analysis for AULSF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price
$0.08
GF Value